Autologous Cd19-Cd20-Nkg2D-Nsbicephali Car-T Cell
Relapsed/Refractory Secondary Central Nervous System Lymphoma
Beijing Boren HospitalCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Relapsed/Refractory Secondary Central Nervous System Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|
Same molecule, other indications
Autologous Cd19-Cd20-Nkg2D-Nsbicephali Car-T Cell is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →